(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 November 2013 (21.11.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/173129 A2

(51) International Patent Classification:
*A61K 48/00* (2006.01) *A61K 45/06* (2006.01)
*A61K 35/76* (2006.01)

(21) International Application Number:
PCT/US2013/040011

(22) International Filing Date:
7 May 2013 (07.05.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

| | | |
|---|---|---|
| 61/647,461 | 15 May 2012 (15.05.2012) | US |
| 61/670,535 | 11 July 2012 (11.07.2012) | US |
| 61/678,555 | 1 August 2012 (01.08.2012) | US |
| 61/691,660 | 21 August 2012 (21.08.2012) | US |
| 61/775,440 | 8 March 2013 (08.03.2013) | US |


(71) Applicants *(for all designated States except US)*: **AVALANCHE AUSTRALIA PTY LTD.** [AU/AU]; c/o MPR Group Pty Ltd., Floor 19, Building HWT Tower, 40 City Road, Southbank, Victoria, 3006 (AU). **LIONS EYE INSTITUTE LIMITED** [AU/AU]; 2 Verdun Street, Nedlands, Western Australia, 6009 (AU).

(72) Inventors; and
(71) Applicants *(for US only)*: **CONSTABLE, Ian, J.** [AU/AU]; 134 Glyde Street, Mosman Park, Western Australia, 6012 (AU). **RAKOCZY, Elizabeth, P.** [AU/AU]; M405/183 West Coast Hwy, Scarborough, Western Australia, 6019 (AU). **LAI, Chooi-may** [AU/AU]; 27 Kildenny Circle, Waterford, Western Australia, 6152 (AU). **CHALBERG, Thomas, W., Jr.** [US/US]; 2749 Carolina Avenue, Redwood City, CA 94028 (US).


(74) Agents: **ORBAI, Lucian** et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

*[Continued on next page]*

(54) Title: TREATMENT OF AMD USING AAV SFLT-1



| Date | OCT CPT | BCVA Snellen Eq |
|---|---|---|
| December 2011 | 704 µm | 20/320 |
| Baseline | 642 µm | 20/250 |
| Day 21 | 472 µm | 20/400 |
| Day 30 | 498 µm | 20/400 |
| Day 60 | 393 µm | 20/200 |
| Day 90 | 361 µm | 20/400 |

FIG. 16

(57) Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase- 1 (sFlt-1) protein to the human subject.

WO 2013/173129 A2

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *with sequence listing part of description (Rule 5.2(a))*

**Published**:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*